NORML Says More Physicians Issue Medical Cannabis Authorizations

Clinicians are moving faster than their institutions

NORML's Oct. 5 post argues that physician adoption of medical cannabis has outpaced the professional bodies and schools that train and credential those doctors.

The post, headlined "Growing Number of Physicians Are Issuing Medical Cannabis Authorizations," carries one passage that frames the whole argument. According to the NORML blog, as more physicians, nurses and others integrate medical cannabis into clinical practice, their medical associations, institutions and educational curricula need to embrace cannabis as a mainstream and established therapeutic option.

That's a demand, not a finding. The excerpt distributed in NORML's feed doesn't include the headcount of authorizing physicians, the jurisdictions covered, or the study design behind the headline. We haven't independently verified a number, so we aren't printing one.

Here's what the framing does tell us. The advocacy case has shifted from "should doctors be allowed to" to "why isn't the profession keeping up with the doctors who already do." That's a more mature argument, and a harder one for regulators to wave off.

The international comparison: where prescribing went mainstream

Countries that moved cannabis into ordinary prescribing channels show both the upside and the friction NORML is pointing at.

Germany is the clearest test case. Since April 2024, its Medical Cannabis Act (MedCanG) has taken medical cannabis out of the Narcotics Act, so physicians no longer need special narcotics prescription forms. Prescribing volumes and telemedicine platforms have followed the lower administrative bar. BfArM, the federal drug regulator, still sits over the supply chain, and imports still dominate.

The United Kingdom runs the opposite model. Since November 2018, only specialist doctors on the General Medical Council's specialist register can initiate prescriptions. Rescheduling opened the door. The specialist gate, along with funding limits, kept most patients outside it.

Canada sits between them. Under the Cannabis Act, in force since October 2018, Health Canada's medical framework lets patients obtain cannabis on a health care practitioner's medical document. Authorization is broad. Professional guidance, though, has long been cautious, and that's the same institutional lag NORML describes in the U.S.

Three regimes, one pattern. Legal permission arrives first. Clinical confidence, training and payer coverage arrive later, if at all.

The INCB, which monitors compliance with the UN drug conventions, has long scrutinized national medical cannabis programs for oversight and diversion risk. Any country where authorizations climb quickly can expect that attention to follow.

What it means for patients, operators and investors

If authorizations keep growing without curriculum and guideline support, the bottleneck shifts from legal access to clinical standards, and that changes who wins.

Patients face a quality-of-recommendation problem. A physician who got no cannabis training in medical school is working from self-directed reading, dosing heuristics and product labels. Reasonable doctors can end up in very different places on THC and CBD ratios, drug interactions and contraindications.

A rising pool of authorizing clinicians usually means a broader, more stable patient base for operators, particularly in markets where adult-use competition has squeezed medical-only models. Physician-led channels also tend to favor products with consistent, lab-verified labeling. Operators with weak testing records should read that as a warning.

For investors, the sharper question is who captures the clinical layer. Telehealth evaluators, clinic networks and education providers all sit between a legal framework and a dispensary sale, a layer that has drawn scrutiny in several countries and will draw more as volumes rise.

NORML's call for medical associations to move is the right pressure point. Without formal guidelines, authorization growth invites exactly the oversight backlash the industry doesn't want.

The questions worth tracking, in order:

• Whether any national or state medical association updates its cannabis guidance in response
• Whether medical schools add cannabis content to required curricula, not just electives
• Whether regulators publish authorization data that can be audited

For full background on this story, see the CannIntel topic hub on physician medical cannabis recommendations.

The next signal to watch is whether NORML or its academic partners publish the underlying authorization counts. Until the data is public, the headline is a direction of travel, not a measurement.